![](images/Newspaper.gif)
Role of Saroglitazar in Non Diabetic Non Alcoholic Fatty Liver Disease Patients: A Retrospective Observational Study
OC21-OC23
Correspondence
Dr. Akash Jaiswal,
Quarter No. 4, ILS Hospital Premises, Kunjawan, Agartala, Tripura, India.
E-mail: akashjaiswal19@gmail.com
Introduction: Non Alcoholic Fatty Liver Disease (NAFLD) is a commonly encountered problem which affects one third of the general population. Saroglitazar, a Peroxisome Proliferator Activated Receptor (PPAR) alpha α and gamma γ agonist has been recently approved for treatment of NAFLD.
Aim: To assess the efficacy of saroglitazar in non diabetic NAFLD patients.
Materials and Methods: It was a retrospective observational study, conducted from October 2020 to March 2021 on 45 non diabetic NAFLD patients, at a tertiary care centre in northeastern India. Liver enzymes, liver fibrosis and liver fat content were compared before and after receiving saroglitazar for 24 weeks. Multiple regression analysis was used to assess percent change in Alanine Transaminase (ALT), Aspartate Transaminase (AST), ALP, bilirubin, Liver Stiffness Measurement (LSM) and Controlled Attenuation Parameter (CAP). The p-values <0.05 were considered as statistically significant.
Results: Mean age of the study population was 46±8.20 years, and there were 24 males and 21 females. Reduction in liver enzymes like Alanine Transaminase (ALT) and Aspartate Transaminase (AST) and fibroscan parameters like Liver Stiffness Measurement (LSM) and Controlled Attenuation Parameter (CAP) were seen. Mean values of ALT and AST at pretreatment status were 85.52±17.12 U/L and 70.02±19.10 U/L, and after treatment were 40.20±12.11 U/L and 37.32±8.31 U/L, respectively (p-value <0.0001 for both ALT and AST). Pretreatment and post-treatment mean values for LSM and CAP were 8.11±2.18 kPa (kilopascal), 365.84±56.22 d/m (decibel/ metre) and 7.20±1.80 kPa, 345.21±35.22 d/m, respectively (p-value=0.021 for LSM and 0.036 for CAP).
Conclusion: Twenty four weeks saroglitazar was effective in treatment of non diabetic NAFLD. It not only reduces hepatocellular inflammation, but also liver fibrosis and liver fat.